MX2022016591A - Moléculas de anticuerpo contra april y usos de las mismas. - Google Patents

Moléculas de anticuerpo contra april y usos de las mismas.

Info

Publication number
MX2022016591A
MX2022016591A MX2022016591A MX2022016591A MX2022016591A MX 2022016591 A MX2022016591 A MX 2022016591A MX 2022016591 A MX2022016591 A MX 2022016591A MX 2022016591 A MX2022016591 A MX 2022016591A MX 2022016591 A MX2022016591 A MX 2022016591A
Authority
MX
Mexico
Prior art keywords
antibody molecules
april
treat
disclosed
prevent
Prior art date
Application number
MX2022016591A
Other languages
English (en)
Inventor
Zachary Shriver
Gregory Babcock
James R Myette
Boopathy Ramakrishnan
Hedy Adari-Hall
Jill Yarbrough
Asher Schachter
Karthik Viswanathan
Andrew M Wollacott
Mohit Mathur
Original Assignee
Visterra Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Visterra Inc filed Critical Visterra Inc
Publication of MX2022016591A publication Critical patent/MX2022016591A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)

Abstract

Se describen moléculas de anticuerpo que se unen específicamente a APRIL. Las moléculas de anticuerpo se pueden usar para tratar, prevenir y/o diagnosticar trastornos, tal como la nefropatía por IgA.
MX2022016591A 2020-06-24 2021-06-24 Moléculas de anticuerpo contra april y usos de las mismas. MX2022016591A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063043558P 2020-06-24 2020-06-24
US202063091002P 2020-10-13 2020-10-13
US202163136950P 2021-01-13 2021-01-13
US202163195527P 2021-06-01 2021-06-01
PCT/US2021/038924 WO2021262999A1 (en) 2020-06-24 2021-06-24 Antibody molecules to april and uses thereof

Publications (1)

Publication Number Publication Date
MX2022016591A true MX2022016591A (es) 2023-04-20

Family

ID=77022225

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022016591A MX2022016591A (es) 2020-06-24 2021-06-24 Moléculas de anticuerpo contra april y usos de las mismas.

Country Status (9)

Country Link
EP (1) EP4172206A1 (es)
JP (1) JP2023531722A (es)
KR (1) KR20230042273A (es)
AU (1) AU2021297315A1 (es)
BR (1) BR112022026639A2 (es)
CA (1) CA3187823A1 (es)
MX (1) MX2022016591A (es)
TW (1) TW202216195A (es)
WO (1) WO2021262999A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202400637A (zh) * 2022-04-25 2024-01-01 美商威特拉公司 April之抗體分子及其用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
ATE151110T1 (de) 1988-09-02 1997-04-15 Protein Eng Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
AU633698B2 (en) 1990-01-12 1993-02-04 Amgen Fremont Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
WO1992020791A1 (en) 1990-07-10 1992-11-26 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0546091B1 (en) 1990-08-29 2007-01-24 Pharming Intellectual Property BV Homologous recombination in mammalian cells
CA2105300C (en) 1991-03-01 2008-12-23 Robert C. Ladner Process for the development of binding mini-proteins
JP3672306B2 (ja) 1991-04-10 2005-07-20 ザ スクリップス リサーチ インスティテュート ファージミドを使用するヘテロ二量体受容体ライブラリー
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
DK0656946T4 (da) 1992-08-21 2010-07-26 Univ Bruxelles Immunoglobuliner uden lette kæder
MY197345A (en) 2015-11-25 2023-06-14 Visterra Inc Antibody molecules to april and uses thereof
BR112019001989A2 (pt) 2016-08-02 2019-08-20 Visterra Inc polipeptídeos projetados e usos dos mesmos

Also Published As

Publication number Publication date
TW202216195A (zh) 2022-05-01
EP4172206A1 (en) 2023-05-03
BR112022026639A2 (pt) 2023-05-09
CA3187823A1 (en) 2021-12-30
WO2021262999A1 (en) 2021-12-30
AU2021297315A1 (en) 2023-02-02
KR20230042273A (ko) 2023-03-28
JP2023531722A (ja) 2023-07-25

Similar Documents

Publication Publication Date Title
EP4285923A3 (en) Antibody molecules to april and uses thereof
PH12019502875A1 (en) Antibody molecules to cd73 and uses thereof
WO2019232244A3 (en) Antibody molecules to cd73 and uses thereof
MX2022008659A (es) Moléculas de anticuerpos específicos contra c5ar1 y usos de estas.
CA3156451A1 (en) ANTIBODIES WITH SPECIFICITY FOR NECTIN-4 AND THEIR USES
WO2017181098A3 (en) Antibody molecules to zika virus and uses thereof
PH12020550141A1 (en) Antibody molecules to cd138 and uses thereof
WO2017019894A8 (en) Combination therapies comprising antibody molecules to lag-3
BR112018012138A2 (pt) moléculas de anticorpo para pd-1 e usos das mesmas
PH12016501482A1 (en) Antibody molecules to tim-3 and uses thereof
MY184757A (en) Antibody molecules to pd-1 and uses thereof
MX2016010360A (es) Moleculas de anticuerpo para el virus del dengue y uso de las mismas.
MX2018000147A (es) Moleculas de anticuerpo que se unen al grupo de diferenciacion 45 (cd45).
MX2019015738A (es) Regimen de dosificacion para anticuerpos anti-tim-3 y usos de los mismos.
EA201890320A1 (ru) Молекулы антител, которые связывают cd79
WO2017083515A3 (en) Antibody molecule-drug conjugates that specifically binds to lipopolysaccharide and uses thereof
MY156767A (en) Anti-angiogenic compounds
MX2021016098A (es) Moleculas de anticuerpos humanizados contra cd138 y usos de las mismas.
WO2008150530A3 (en) Cripto binding molecules
EA202192796A1 (ru) Tigit и pd-1/tigit-связывающие молекулы
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
PH12018501739A1 (en) Antibodies for il-17c
MX2022016591A (es) Moléculas de anticuerpo contra april y usos de las mismas.
MX2021011830A (es) Anticuerpo anti fgf23.
MX2019007356A (es) Polipeptidos de union y metodos para fabricarlos.